Skip to content

Repositioning OSTX-2

OncoStemyx is reformulating OSTX-2 to improve bioavailability by 4X.

Our goal is to file an IND using the 505(b)(2) exemption.

Intellectual Property​

Four patents pending with 20-year patent protection:

The 505(b)(2) and the ‘3/7 Rule’: